Kazia Therapeutics (KZIA): Phase IIa Shows Good Safety, Consistent Efficacy

Rhea-AI Summary

Kazia's latest interim data analysis from its Phase IIa study of paxalisib in glioblastoma multiforme (GBM) shows promising results. The study reports progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. The safety data at the full 60mg dose indicates a favorable profile. Additionally, Kazia increased its valuation to US$184 million or US$14.55 per ADR, reflecting higher success probability for paxalisib. This adjustment follows an October US$18 million capital raise, enhancing investor outlook.

Positive

• PFS of 8.4 months and OS of 17.5 months reported for paxalisib.
• Safety profile of paxalisib at 60mg dose shows favorable results.
• Valuation increased to US$184 million from US$104 million.
• Probability of success for paxalisib raised to 35% from 20%.
• Completed an US$18 million capital raise, strengthening financial position.

Negative

• None.

LONDON, UK / ACCESSWIRE / December 3, 2020 / Kazia presented the results from a new interim data analysis of its ongoing Phase IIa study of paxalisib in glioblastoma multiforme (GBM). The data were consistent with previous data and showed progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months. Importantly, Kazia also published some of the first safety data at the full 60mg dose, which show an attractive profile compared to other members of this class.

We have increased our valuation to US$184m or US$14.55 per ADR from US$104m or US$10.98 per ADR. This is driven by increasing our probability of success for paxalisib in GBM to 35% (US$151.8m) from 20% (US$81.8m) and the October US$18m raise (31.5m shares at A$0.80).

Click here to view the full report.

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036
healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv

SOURCE: Edison Investment Research Limited

View source version on accesswire.com:
https://www.accesswire.com/619154/Kazia-Therapeutics-KZIA-Phase-IIa-Shows-Good-Safety-Consistent-Efficacy

FAQ

What are the latest results for Kazia's KZIA Phase IIa study of paxalisib?

Kazia reported a progression-free survival (PFS) of 8.4 months and overall survival (OS) of 17.5 months in its Phase IIa study of paxalisib for glioblastoma.

How has Kazia's valuation changed based on the new data?

Kazia's valuation increased to US$184 million or US$14.55 per ADR from a previous valuation of US$104 million.

What is the probability of success for paxalisib according to the latest analysis?

The probability of success for paxalisib in treating glioblastoma has been updated to 35% from the previous 20%.

Did Kazia raise capital recently, and how much was it?

Yes, Kazia raised US$18 million through the issuance of 31.5 million shares at A$0.80.